$30 Billion Deal, page-4951

Hmmmm, this info has caused me to see a problem here. Let’s say both the COVID trials and the HIV trials are overwhelmingly successful. Then BIT225 gets approved for both indications. How are you going to price it? For COVID it would have to be comparable or cheaper than other effective drugs on the market for COVID, which then creates an issue regarding HIV treatment. How can you charge an arm and two legs for a drug that treats/maybe cures HIV when the same drug is being sold all over the world at average prices, or maybe even available on the PBS etc for peanuts..